TENDER AND SUPPORT AGREEMENTTender and Support Agreement • January 13th, 2020 • Bay City Capital LLC • Pharmaceutical preparations • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 10, 2020, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Bald Eagle Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and each of the entities set forth on Schedule A hereto (each, a “Stockholder” and collectively, the “Stockholders”). All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).
AGREEMENT WITH RESPECT TO SCHEDULE 13DAgreement With Respect to Schedule 13d • June 19th, 2007 • Bay City Capital LLC • Biological products, (no disgnostic substances)
Each of Bay City Capital LLC, Bay City Capital Management IV LLC, Bay City Capital Fund IV, L.P. and Bay City Capital Fund IV Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the common stock of VIA Pharmaceuticals, Inc. is filed on behalf of each of them.
AGREEMENT WITH RESPECT TO SCHEDULE 13DAgreement With Respect to Schedule 13d • May 8th, 2006 • Bay City Capital LLC • In vitro & in vivo diagnostic substances
Each of Bay City Capital LLC, Bay City Capital Management IV LLC, Bay City Capital Fund IV, L.P. and Bay City Capital Fund IV Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the common stock of NeoRx Corporation is filed on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • October 14th, 2014 • Bay City Capital LLC • Pharmaceutical preparations
Each of Bay City Capital LLC, Bay City Capital Management V LLC, Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the securities of Dermira, Inc. is filed on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • July 29th, 2016 • Bay City Capital LLC
Each of Bay City Capital LLC, Bay City Capital Management IV LLC, Bay City Capital Fund IV, L.P., and Bay City Capital Fund IV Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the securities of Madrigal Pharmaceuticals, Inc. is filed on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • June 1st, 2020 • Bay City Capital LLC • Pharmaceutical preparations
Each of Fred B. Craves, Ph.D., Bay City Capital LLC, Bay City Capital Management IV LLC, Bay City Capital Fund IV, L.P., and Bay City Capital Fund IV Co-Investment Fund, L.P. hereby express its agreement that the attached Amendment to Schedule 13D (and any further amendments thereto) relating to the securities of Madrigal Pharmaceuticals, Inc. is filed on behalf of each of them.
AGREEMENT WITH RESPECT TO SCHEDULE 13GAgreement With Respect to Schedule 13g • February 11th, 2008 • Bay City Capital LLC • Pharmaceutical preparations
Each of Bay City Capital LLC, Bay City Capital Management IV LLC, Bay City Capital Fund IV, L.P. and Bay City Capital Fund IV Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13G (and any amendments thereto) relating to the common stock of MAP Pharmaceuticals, Inc. is filed on behalf of each of them.
AGREEMENT WITH RESPECT TO SCHEDULE 13DAgreement With Respect to Schedule 13d • November 21st, 2007 • Bay City Capital LLC • Electromedical & electrotherapeutic apparatus
Each of Bay City Capital LLC, Bay City Capital Management IV LLC, Bay City Capital Fund IV, L.P. and Bay City Capital Fund IV Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the common stock of EnteroMedics Inc. is filed on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • May 22nd, 2013 • Bay City Capital LLC • In vitro & in vivo diagnostic substances
Each of Bay City Capital LLC, Bay City Capital Management V LLC, Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the securities of Interleukin Genetics, Inc. is filed on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • May 27th, 2016 • Bay City Capital LLC • Pharmaceutical preparations
Each of Bay City Capital LLC, Bay City Capital Management V LLC, Bay City Capital Fund V, L.P., Bay City Capital Fund V Co-Investment Fund, L.P. and Bay City Capital Coöperatief U.A. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the securities of Merus, N.V. is filed on behalf of each of them.
AGREEMENT WITH RESPECT TO SCHEDULE 13GAgreement With Respect to Schedule 13g • May 12th, 2015 • Bay City Capital LLC • Surgical & medical instruments & apparatus
Each of Bay City Capital LLC, Bay City Capital Management IV LLC, Bay City Capital Fund IV, L.P. and Bay City Capital Fund IV Co-Investment Fund, L.P. hereby expresses its agreement that the attached Schedule 13G (and any amendments thereto) relating to the common stock of Nevro Corp. is filed on behalf of each of them.
EXHIBIT I AGREEMENT OF JOINT FILINGJoint Filing Agreement • September 2nd, 2016 • Bay City Capital LLC • Surgical & medical instruments & apparatus
Each of Bay City Capital LLC, Bay City Capital Management IV LLC, Bay City Capital Fund IV, L.P. and Bay City Capital Fund IV Co-Investment Fund, L.P. hereby expresses its agreement that the attached Schedule 13G/A relating to the common stock of Nevro Corp. is filed on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • August 2nd, 2012 • Bay City Capital LLC • Pharmaceutical preparations
Each of Bay City Capital LLC, Bay City Capital Management V LLC, Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the common stock of Hyperion Therapeutics, Inc. is filed on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • June 7th, 2013 • Bay City Capital LLC • Pharmaceutical preparations
Each of Bay City Capital LLC, Bay City Capital Management V LLC, Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the securities of Epizyme, Inc. is filed on behalf of each of them.
Madrigal Pharmaceuticals, Inc. Lock-Up AgreementLock-Up Agreement • December 13th, 2019 • Bay City Capital LLC • Pharmaceutical preparations
